scholarly journals COVID-19 antivirals must not affect HIV drug supply

2021 ◽  
Author(s):  
Melissa Barber ◽  
Ameet Sarpatwari ◽  
Christa Cepuch
Keyword(s):  
Author(s):  
Kornilova E. B. ◽  
◽  
Holovnya-Voloskova M. E. ◽  
Kornilov M. N. ◽  
Zavyalov A. A. ◽  
...  

Author(s):  
Thomas F. Babor ◽  
Jonathan Caulkins ◽  
Benedikt Fischer ◽  
David Foxcroft ◽  
Keith Humphreys ◽  
...  

Among the 47 options reviewed in this book, most show some evidence of effectiveness in at least one country, but the evidence is less than definitive for many others, either because the interventions are ineffective, or the research is inadequate. Unfortunately, policies that have shown little or no evidence of effectiveness continue to be the preferred options of many countries and international organizations. The evidence reviewed in this book supports two overarching conclusions. First, an integrated and balanced approach to evidence-informed drug policy is more likely to benefit the public good than uncoordinated efforts to reduce drug supply and demand. Second, by shifting the emphasis toward a public health approach, it may be possible to reduce the extent of illicit drug use, prevent the escalation of new epidemics, and avoid the unintended consequences arising from the marginalization of drug users through severe criminal penalties.


Author(s):  
María Fabiana Jorge

With the outbreak of the Coronavirus there is a new realization of the vulnerabilities of the U.S. drug supply chain. However, while such concerns may have been amplified by the pandemic, they preceded Covid-19 and were well documented before 2020. Indeed, in past years the U.S. Congress held several hearings addressing potential vulnerabilities in the U.S. drug supply chain, in part due to the increasing dependency on China as a dominant supplier of active pharmaceutical ingredients (APIs) and some finished pharmaceutical products. These vulnerabilities go well beyond health policy and constitute a national security concern. The article addresses how U.S. trade policy plays a significant role in shaping the pharmaceutical industry at home and abroad and is in part responsible for some of the current vulnerabilities of the U.S. drug supply chain.


2021 ◽  
pp. 1-2
Author(s):  
Rachel S. Wightman ◽  
Earth Erowid ◽  
Fire Erowid ◽  
Sylvia Thyssen ◽  
Mary Wheeler ◽  
...  

2021 ◽  
pp. 009145092110354
Author(s):  
Jennifer J. Carroll

Drug checking is an evidence-based strategy for overdose prevention that continues to operate (where it operates) in a legal “gray zone” due to the legal classification of some drug checking tools as drug paraphernalia—the purview of law enforcement, not public health. This article takes the emergence of fentanyl in the U.S. drug supply as a starting point for examining two closely related questions about drug checking and drug market expertise. First, how is the epistemic authority of law enforcement over the material realities of the drug market produced? Second, in the context of that authority, what are the socio-political implications of technologically advanced drug checking instruments in the hands of people who use drugs? The expertise that people who use drugs maintain about the nature of illicit drug market and how to navigate the illicit drug supply has long been discounted as untrustworthy, irrational, or otherwise invalid. Yet, increased access to drug checking tools has the potential to afford the knowledge produced by people who use drugs a technological validity it has never before enjoyed. In this article, I engage with theories of knowledge production and ontological standpoint from the field of science, technology, and society studies to examine how law enforcement produces and maintains epistemic authority over the illicit drug market and to explore how drug checking technologies enable new forms of knowledge production. I argue that drug checking be viewed as a form of social resistance against law enforcement’s epistemological authority and as a refuge against the harms produced by drug criminalization.


Author(s):  
Christopher M Jones ◽  
Faraah Bekheet ◽  
Ju Nyeong Park ◽  
G Caleb Alexander

Abstract The opioid overdose epidemic is typically described as having occurred in three waves, with morbidity and mortality accruing over time principally from prescription opioids (1999-2010), heroin (2011-2013) and illicit fentanyl and other synthetic opioids (2014-present). However, the increasing presence of synthetic opioids mixed into the illicit drug supply, including with stimulants such as cocaine and methamphetamine, as well as rising stimulant-related deaths, reflects the rapidly evolving nature of the overdose epidemic posing urgent and novel public health challenges. We synthesize the evidence underlying these trends, consider key questions such as where and how concomitant exposure to fentanyl and stimulants is occurring, and identify actions for key stakeholders regarding how these emerging threats, and continued evolution of the overdose epidemic, can best be addressed.


Author(s):  
Marianne Jahre ◽  
Luc Dumoulin ◽  
Langdon B. Greenhalgh ◽  
Claudia Hudspeth ◽  
Phillips Limlim ◽  
...  

Author(s):  
Kazushige Ijuin ◽  
Fumiyo Kusu ◽  
Rieko Matsuda ◽  
Yuzuru Hayashi

2021 ◽  
pp. injuryprev-2020-043968
Author(s):  
Jewell Johnson ◽  
Lia Pizzicato ◽  
Caroline Johnson ◽  
Kendra Viner

Reports from active drug users state that xylazine, the veterinary tranquilliser, has been increasing in the illicit drug supply in Philadelphia. To describe trends and characteristics of unintentional deaths from heroin and/or fentanyl overdose with xylazine detections occurring in Philadelphia, Pennsylvania, the Philadelphia Department of Public Health analysed data on deaths from unintentional heroin and/or fentanyl overdose from the Philadelphia Medical Examiner’s Office over a 10-year period (2010–2019). Xylazine went from being detected in less than 2% cases of fatal heroin and/or fentanyl overdose between 2010 and 2015 to 262 (31%) of the 858 fatal heroin and/or fentanyl overdose cases in 2019. Currently, information is limited on the presence of xylazine in continental United States. Xylazine’s association with adverse outcomes in other locations indicates that potential health consequences should also be monitored in the USA. Whenever possible, jurisdictions should consistently test for xylazine.


2021 ◽  
Vol 8 (4) ◽  
pp. 5-12
Author(s):  
E.A. Telnova ◽  
A.V. Belova ◽  
A.A. Zagoruichenko

The article analyzes the results of monitoring the availability and quality of the drug supply system among the population of various age groups and financial situation. The purpose of this study is to study the satisfaction of citizens in the drug supply system in Russia and to build a medical and social portrait of the patient, which was developed based on the analysis of the results of a sociological survey conducted in dynamics for 2019-2021. In the course of the research, such methods as: sociological, study and generalization of experience, analytical, methods of descriptive statistics were used. The results of the sociological study indicate the need for additional work to improve the availability and quality of LLR and the level of awareness of patients about the system of drug reimbursement. The obtained data can be used for health management bodies at various hierarchical levels, confirm the special social significance of solving this problem and the need to introduce preventive measures to involve patients in healthy lifestyle, increase public confidence in domestic drugs.


Sign in / Sign up

Export Citation Format

Share Document